Moneycontrol

You are Here : DRL launches Renvela generic in US, price target at Rs 2200: HDFC Securities

Tuesday, 09:16

The pharma major Dr Reddys Laboratories (DRL) has launched kidney disease drug Renvela generic in the US market. How big an opportunity can this be for DRL and what does it do to Aurobindo Pharma. In an interview to CNBC-TV18, Amey Chalke of HDFC Securities shared his views and readings on the same.
OCT 19, 2017
04:37 PM

cnbc tv18 shows

Search
All Shows
Go

NOW PLAYING

Markets Today

What's happened in the markets through the day? What are top experts & brokerages betting on? What's happening in the global economy? What about market moving business stories? Which government policies will impact the markets? For all this & more, watch Markets Today - a show that g ... more »

mytv on mobile

Track your portfolio on the go with

moneycontrol app

Sections
Follow us on
Available On